Skip to content

Cerebrolysin

A porcine brain-derived peptide preparation with neurotrophic properties, approved in several countries for stroke recovery and cognitive disorders.

BModerateModerate Data
Last updated 37 citations
TL;DR

Cerebrolysin is a liquid made from enzyme-digested pig brain protein, given by injection or drip. It is approved in Austria, Russia, China and dozens of other countries for stroke, head injury and dementia — but not in the US, UK, Canada or Australia. The evidence is genuinely split: a large body of positive trials exists, but most comes from one manufacturer-linked research network, while the independent Cochrane reviews found no benefit on survival in stroke and flagged a possible rise in non-fatal serious side effects. It is not something you can buy or take at home.

What is Cerebrolysin?

Cerebrolysin is a peptide preparation derived from porcine brain tissue that mimics the action of naturally occurring neurotrophic factors. It has been approved in dozens of countries for the treatment of stroke, traumatic brain injury, and dementia. It contains a mixture of low-molecular-weight peptides and free amino acids; its manufacturer describes blood-brain-barrier passage as established indirectly, from animal pharmacodynamics, rather than directly measured.

What Cerebrolysin Is Investigated For

Cerebrolysin is a porcine brain-derived peptide preparation with the deepest clinical evidence base of any peptide in this reference outside the FDA-approved incretins — approved in dozens of countries for acute ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease, supported by multiple large randomized trials and meta-analyses. The strongest evidence is for stroke recovery and rehabilitation, where the CARS trials and multiple meta-analyses document modest but measurable motor-recovery benefits, and for vascular dementia and mild-to-moderate Alzheimer's, where cognitive endpoint improvements have been reported across several RCTs. A 2026 prospective Thai cohort (Asian J Neurosurg) in moderate TBI with nonoperative intracerebral hemorrhage reported a 6-month survival difference favoring Cerebrolysin (59.4% vs 27.8%) that is almost certainly too large to be real — a 72% six-month mortality in moderate TBI under standard care is several times published rates, which points to a reporting or case-mix problem in the source rather than to an enormous treatment effect alongside better CRS-R and Barthel Index scores, extending the CAPTAIN TBI evidence base — though the single-blind non-randomized design limits causal inference. The honest caveats are real and important: trial results have been mixed, with the large CASTA stroke trial failing to meet its primary endpoint; effect sizes in meta-analyses are modest rather than transformative; much of the literature is manufacturer-sponsored or concentrated in Russian, Chinese, and CIS research networks; and independent Western regulatory confirmation has not occurred — Cerebrolysin has never been FDA-approved. A 2026 regulatory-landscape analysis (Int J Risk Saf Med) explicitly confirmed the jurisdictional split: only the Russian Federation's clinical practice guideline recommends Cerebrolysin in Alzheimer's disease, while EU, UK and US guidelines do not mention nootropics as an option at all; CIS-wide status concerns registration and essential-medicines listing rather than guideline endorsement; US, EU, and UK guidelines do not mention it. It is also a heterogeneous biological preparation (~15% peptides, ~85% free amino acids from porcine brain tissue) rather than a single defined peptide, which matters for interpreting efficacy data and distinguishing the branded product from unverified imitations.

Stroke recovery and rehabilitation — large trial base, but the two Cochrane reviews and the largest blinded trial (CASTA) are negative, and the positive literature comes largely from one sponsor-linked network
Moderate70%
Traumatic brain injury recovery
Moderate70%
Alzheimer's disease and dementia
Moderate70%
Cognitive enhancement
Emerging50%

History & Discovery

Cerebrolysin was developed by the Austrian pharmaceutical company EVER Neuro Pharma (originally Ebewe) beginning in the 1970s, with clinical use accelerating through the 1980s and 1990s. The preparation is produced by controlled enzymatic hydrolysis of porcine brain tissue, yielding a mixture of low-molecular-weight peptides and free amino acids, filtered to remove larger proteins. The exact split is less settled than it is usually presented: the primary source (Hartbauer 2001) reports 25 percent peptides under 10 kDa and 75 percent free amino acids, the 15/85 ratio is also widely quoted, and the Austrian label states no split at all — it specifies only 215.2 mg of proteolytic peptide fraction from porcine brain protein per mL. The claim embedded in the product design is that this mixture contains or mimics multiple endogenous neurotrophic factors — BDNF, GDNF, NGF, CNTF — in a form small enough to cross the blood-brain barrier after parenteral administration. Cerebrolysin is unusual among the peptides in this reference: it is not a single defined molecule but a complex biological preparation, and it has been through an extensive set of randomized controlled trials — including the CASTA trial in ischemic stroke and multiple Alzheimer's disease trials. Regulatory approval followed in Russia, China, Austria, and numerous CIS countries; today the product is registered in over 40 jurisdictions for indications including acute ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease. It has never received FDA approval in the United States, where the combination of a complex biologic of animal origin and evolving standards for neurological trial endpoints has kept it outside the approved formulary. Clinical trial results have been mixed: some large stroke trials (notably CASTA) did not meet their primary endpoints, while subgroup and later-phase analyses and meta-analyses have reported modest benefits in motor recovery and cognitive endpoints. The evidence is the strongest of any peptide in this reference, but the effect sizes are modest and the regulatory verdicts are jurisdiction-dependent.

How It Works

Cerebrolysin provides the brain with building blocks and growth signals similar to those naturally produced during brain development. It helps protect existing brain cells and may support the growth of new neural connections after injury.

Cerebrolysin is routinely described as mimicking endogenous neurotrophic factors such as BDNF, GDNF, NGF and CNTF, and that framing deserves to be stated more carefully than it usually is. No published analysis shows the preparation contains any of those factors; the resemblance is inferred from the behaviour of the peptide fraction in neuronal culture, and the named-factor list does not appear in the regulatory label. The foundational 2001 work points the other way on BDNF specifically: an artificial amino-acid solution failed to reproduce the protective effect, implicating the peptide fraction — but so did BDNF itself and serum supplementation, which protected nothing in that model while Cerebrolysin did. Whatever the active peptides are doing, it is not straightforwardly BDNF-like, and they have never been individually identified. What is reasonably supported: the preparation promotes neuronal survival through anti-apoptotic mechanisms, enhances synaptic plasticity and neurogenesis in culture and animal models, reduces infarct volume in rodent stroke models, and reduces amyloid pathology in transgenic mice. The manufacturer's label adds stabilisation of microcirculation, increased glucose-transporter density at the blood-brain barrier and reduced cerebral lactate — all explicitly from animal models. Blood-brain-barrier passage is weaker than the usual phrasing implies. The Austrian label states that pharmacokinetic parameters cannot be measured directly for a preparation of this kind, and that passage is established indirectly: intracerebroventricular and peripheral administration produce identical pharmacodynamic effects in animals, which the label itself calls indirect evidence that components cross the barrier. That is a reasonable inference, not a demonstration, and it means no one can say which components cross or at what concentration.

Evidence Snapshot

Overall Confidence50%

Human Clinical Evidence

Large in volume, genuinely contested in direction — which is a different thing from strong. Dozens of randomized trials and meta-analyses exist, and the largest controlled dataset (C-REGS2, 1769 patients across 16 countries) is positive. But the two independent Cochrane reviews are not. For acute ischaemic stroke the 2023 review found moderate-certainty evidence of no benefit on all-cause death, moderate-certainty evidence of a possible increase in non-fatal serious adverse events, and no trial reporting death-or-dependence at follow-up at all. For vascular dementia every outcome is graded very low quality, with the reviewers concluding the supporting evidence base is weak. The largest blinded stroke trial, CASTA (n=1070), was neutral on its confirmatory endpoint. The positive literature is real and substantial but is produced overwhelmingly by one manufacturer-linked investigator network, while the negative assessments come from Cochrane groups and national HTA bodies with no such ties.

Animal / Preclinical

Extensive and consistently supportive across models of stroke, traumatic brain injury and neurodegeneration, including reduced infarct volume and amyloid reduction in transgenic mice. The caveat that applies to the whole field applies here: preclinical neuroprotection has an exceptionally poor record of translating to stroke outcomes in humans, and Cerebrolysin's own largest blinded trial is a case in point.

Mechanistic Rationale

Weaker than usually stated, and this page previously overstated it. The manufacturer's own label says pharmacokinetic parameters cannot be measured directly and that blood-brain-barrier passage is established only indirectly, by the observation that central and peripheral administration produce the same pharmacodynamic effects. The active peptides have never been identified. Neurotrophic-factor resemblance is inferred from activity in culture rather than from composition — no analysis shows the preparation contains BDNF, GDNF, NGF or CNTF, and in the foundational 2001 paper BDNF itself failed to protect neurons where Cerebrolysin succeeded.

Research Gaps & Open Questions

What the current literature has not yet settled about Cerebrolysin:

  • 01Replication of efficacy findings across independent research groups and regulatory regions — much of the clinical literature is concentrated in manufacturer-sponsored trials or in Russian, Chinese, and CIS clinical networks, and independent Western regulatory confirmation has not occurred.
  • 02Mechanism of action at the component level — Cerebrolysin is a heterogeneous preparation and the specific peptides or peptide combinations responsible for observed clinical effects are not fully identified.
  • 03Comparative effectiveness vs. standard stroke rehabilitation alone and vs. other neuroprotective agents — head-to-head trials are limited.
  • 04Long-term outcomes beyond 12 months after a treatment course — recent propensity-matched cohort work has begun to characterize 12-month functional recovery after thrombectomy + Cerebrolysin, but extended follow-up across the broader indication set remains inconsistent.
  • 05Standardization of dosing across indications — the range of 5–50 mL/day across approved indications reflects empirical practice rather than rigorous dose-finding trials.
  • 06Optimal repeat-course interval for chronic neurodegenerative indications (vascular dementia, Alzheimer's) has not been rigorously established.

Forms & Administration

Cerebrolysin is administered via intravenous or intramuscular injection. Treatment courses typically last 10-20 days with daily infusions. It requires clinical administration. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

Approved clinical protocols use 10–50 mL per day administered intravenously (typically diluted in saline and infused over 20–60 minutes) or by intramuscular injection. For acute ischemic stroke, 30–50 mL/day IV is the commonly used dose. For Alzheimer's disease and vascular dementia, 10–30 mL/day IV or IM is typical. For mild cognitive impairment, 5–10 mL/day IM has been used in some protocols. Formulation is a 215.2 mg/mL aqueous concentrate — so a 10 mL dose delivers roughly 2.15 g of peptide-amino-acid mixture.

Frequency

Daily dosing, five days per week, with weekends off, is the most common schedule. Courses typically run as continuous daily infusions over the treatment window rather than chronic long-term daily dosing.

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Cycle Length

Approved protocols are structured as discrete treatment courses rather than continuous long-term therapy. Acute ischemic stroke courses run 10–21 days starting within days of the event. Alzheimer's and dementia courses typically run 4 weeks, often repeated at 2–3 month intervals based on clinical response. Traumatic brain injury courses run 10–30 days, sometimes with repeat courses. Long-term continuous daily use is not part of any approved protocol.

Protocol Notes

Cerebrolysin is a clinic-administered product, not a self-injection peptide. Intravenous infusion requires dilution in saline (typically 100–250 mL) and infusion over 20–60 minutes; intramuscular injection is limited to smaller volumes (up to 5 mL per site). Home IV administration is not the approved route and is not recommended — infusion reactions, allergic response, and asepsis all argue for clinical oversight. A critical clinical point: Cerebrolysin is not a single peptide. It is a heterogeneous biological preparation derived from porcine brain tissue. Batch-to-batch consistency is maintained by the manufacturer but the product is compositionally complex in a way that a synthetic peptide is not. Clinical trial data supports the specific EVER Pharma preparation; generic or unverified imitation products cannot be assumed to behave equivalently. Porcine origin also introduces considerations for patients who avoid porcine products for religious, cultural, or medical reasons (e.g., certain allergic profiles). Clinicians typically disclose the porcine origin before initiating therapy.

Cerebrolysin is not FDA-approved in the United States. It is approved in Russia, China, Austria, and over 40 other countries for specified neurological indications under their national regulatory frameworks. International approval does not constitute FDA approval. Any use outside jurisdictions where it is approved, or outside the approved indications, is not authorized medical care.

Timeline of Effects

Onset

Cerebrolysin is used for structural recovery endpoints rather than acute symptomatic effect, and onset should be understood accordingly. In acute ischemic stroke, clinically meaningful neurological improvement is typically measured at 30, 60, and 90 days after the start of the treatment course — not within hours of an infusion. Subjective cognitive change in Alzheimer's and dementia trials is typically measured at the end of a 4-week course rather than acutely.

Peak Effect

Peak effect in approved protocols is typically measured at the end of the treatment course (2–4 weeks) or at the primary endpoint visit (30–90 days post-treatment). Stroke recovery trials typically measure peak motor and functional gains at 90 days. Cognitive endpoint improvement in dementia trials is assessed at course completion and again at follow-up.

After Discontinuation

Effect persistence varies by indication. In stroke recovery trials, motor and cognitive benefits measured at the 90-day primary endpoint have shown varying persistence in longer follow-up — some trials have reported sustained benefit at 6–12 months, others have shown convergence with placebo arms over time. In dementia protocols, repeated courses are the norm because benefits tend to decline without continued treatment.

Monitoring & Measurement

Bloodwork & Labs

  • •Renal function (creatinine, eGFR) — severe renal impairment is a labelled contraindication, so this is the one lab that gates eligibility
  • •Blood pressure — specifically if an antidepressant or MAO inhibitor is co-prescribed, where the label documents a possible pressure rise at 30 to 40 mL doses
  • •Basic metabolic panel — routine context for a repeated parenteral amino-acid-containing preparation

Functional & Performance Tests

  • •NIH Stroke Scale (NIHSS) and modified Rankin Scale — the endpoints used across the stroke trials; mRS at 90 days is the outcome clinicians and trialists actually care about
  • •Action Research Arm Test or an equivalent upper-limb measure where motor recovery is the goal, as used in the CARS trials
  • •MMSE, ADAS-cog or MoCA for the dementia and cognitive indications
  • •Glasgow Outcome Scale for traumatic brain injury

When to Test

Assess against a documented pre-treatment baseline, then at the end of the course and again at 90 days, which is where the trial evidence sits. Renal function before starting; blood pressure at each visit if on an antidepressant or MAO inhibitor.

Interpretation & Notes

Monitoring here is about honest attribution more than safety surveillance. Cerebrolysin is given in exactly the settings — acute stroke, post-TBI, early dementia — where substantial spontaneous recovery is expected, where intensive rehabilitation is running in parallel, and where caregivers and clinicians badly want improvement. That is the configuration in which uncontrolled impressions are least reliable, and it is a large part of why the open-label evidence for this compound looks so much better than the blinded evidence. Recording a real baseline on a validated scale before the first dose, and re-scoring at 90 days, is the only way an individual course produces interpretable information. Note too that the trial response rates are reported as Mann-Whitney effect sizes rather than responder percentages, so there is no published threshold defining an individual responder. All of these instruments require a trained assessor; none is a home measurement.

Common Questions

Is Cerebrolysin FDA-approved?

Cerebrolysin is not FDA-approved in the United States but is approved in dozens of countries, primarily in Eastern Europe, Russia, the CIS states and parts of Asia, for neurological conditions. Note that the widely-repeated 'over 40 countries' figure traces to manufacturer materials rather than to any regulatory source, and the manufacturer's own product site gives no number — verified national authorisations include Austria (the country of origin), Russia, Armenia, Belarus, Kazakhstan and Uzbekistan.

How does Cerebrolysin compare to Semax?

Both target cognitive function, but Cerebrolysin is a complex mixture of peptides given intravenously, while Semax is a single synthetic peptide typically given intranasally. Cerebrolysin has more extensive clinical trial data.

Who Cerebrolysin Is NOT For

Contraindications
  • •Known hypersensitivity to Cerebrolysin, to porcine-derived products, or to any component of the formulation.
  • •Status epilepticus — this is the actual labelled contraindication, and it is narrower than the epilepsy contraindication often reported second-hand. Epilepsy itself is not contraindicated.
  • •Severe renal impairment — listed as a contraindication in the manufacturer's prescribing information alongside status epilepticus and hypersensitivity.
  • •Epilepsy and grand mal seizure disorders — a labelled precaution rather than a contraindication, because seizure frequency may increase. Individual grand mal seizures and one case of convulsion have been reported in association with Cerebrolysin as very rare adverse events, so the caution is grounded in post-marketing experience rather than being merely theoretical.
  • •Pregnancy — safety not established; manufacturer labeling advises against use unless clearly needed.
  • •Breastfeeding — limited data; manufacturer advises against use.
  • •Religious or cultural avoidance of porcine products — the porcine origin is a meaningful consideration that should be disclosed before treatment.

Drug & Supplement Interactions

Clinical drug interactions for Cerebrolysin have been studied more extensively than for most peptides in this reference, though the literature is still limited versus conventional drugs. The manufacturer's label flags a specific, dose-dependent interaction with antidepressants and MAO inhibitors rather than a merely theoretical one: it instructs that additive effects be watched for, that the antidepressant dose be reduced in such cases, and states that doses of 30 to 40 mL of Cerebrolysin combined with high doses of MAO inhibitors can produce a rise in blood pressure. Two pharmaceutical incompatibilities are also labelled and are easy to miss: Cerebrolysin must not be co-administered in the same infusion as balanced amino-acid solutions, and it is incompatible with solutions that shift pH outside roughly 5.0 to 8.0 and with lipid-containing solutions. Compatible diluents are 0.9% saline, Ringer's solution or 5% glucose. Co-administration with thrombolytics (alteplase) in acute ischemic stroke has been studied in dedicated trials (CEREHETIS series) and does not appear to increase hemorrhagic transformation rates, supporting combined use in reperfusion-eligible stroke patients. More recent meta-analytic and pooled-analysis work has extended this safety picture to mechanical thrombectomy — the modern standard of care for large-vessel-occlusion stroke — with adjunct Cerebrolysin showing functional-recovery benefit without increased hemorrhagic transformation across observational cohorts. Concurrent use with standard stroke rehabilitation, antihypertensives, statins, and antiplatelet agents has not shown problematic interactions in trial populations. Patients on any psychiatric medications, particularly MAOIs or complex antidepressant regimens, should have Cerebrolysin use reviewed by their prescribing clinician. Concurrent use with other nootropic peptides (Semax, Selank) is common in Russian clinical practice but has not been formally studied for interaction safety.

Safety Profile

Safety Information

Common Side Effects

Dizziness — particularly if the injection or infusion is given too quicklySensation of heat, flushing or sweatingAgitation, which can present as aggression, confusion or insomnia and is thought to be an extension of the intended activating effectInjection or infusion site reactions — redness, itching, burningLoss of appetite

Cautions

  • • Not FDA-approved in the US
  • • Parenteral only — doses up to 5 mL may be given intramuscularly and up to 10 mL intravenously, while doses above 10 mL are given as a diluted infusion; there is no oral form
  • • Contraindicated in status epilepticus and severe renal impairment — note that epilepsy itself is a precaution, not a contraindication, though seizure frequency may increase
  • • Rare reports of individual grand mal seizures and one convulsion case in post-marketing data
  • • The 2023 Cochrane review found moderate-certainty evidence of an increase in non-fatal serious adverse events (RR 2.39), most pronounced at the common 30 mL for 10 days regimen
  • • Porcine-derived — not suitable for some patients

What We Don't Know

The central unresolved question is not dosing or duration but whether the effect is real. The 2023 Cochrane review of acute ischaemic stroke found moderate-certainty evidence of no benefit on all-cause death, moderate-certainty evidence of no difference in the total number of patients with serious adverse events, and moderate-certainty evidence of a possible increase in non-fatal serious adverse events — and noted that none of the seven included trials reported poor functional outcome (death or dependence at end of follow-up) at all, which is the outcome that matters most to patients. The vascular dementia review graded every outcome very low quality. Against that, a large body of positive trials and meta-analyses exists, but it is produced almost entirely by one sponsor-linked investigator network. Optimal treatment duration, long-term cognitive benefit, and the identity of the active peptides all remain open behind that larger question.

Myths & Misconceptions

Myth

Cerebrolysin is FDA-approved.

Reality

Cerebrolysin is not FDA-approved for any indication in the United States. It is approved in dozens of countries including Austria, Russia, China, and most CIS states under their national frameworks. International approval does not equal FDA approval, and Cerebrolysin has not been through the FDA new drug application process for its approved indications.

Myth

Cerebrolysin is a single peptide.

Reality

Cerebrolysin is a heterogeneous biological preparation derived from porcine brain tissue, containing a mixture of low-molecular-weight peptides and free amino acids in a ratio reported variously as 25/75 (the primary source) or 15/85, and not stated at all on the regulatory label. It is not a defined synthetic molecule. This is important for interpreting efficacy data and for distinguishing the branded EVER Pharma product from unverified imitations.

Myth

You can self-administer Cerebrolysin at home the same way you inject synthetic peptides.

Reality

Cerebrolysin is an IV or IM product administered in a clinical setting. IV infusion requires saline dilution and monitored infusion over 20–60 minutes, with standard precautions against infusion reactions and allergic response. Home self-administration is not the approved route and carries meaningful safety risk.

Myth

Cerebrolysin is a proven cure for Alzheimer's disease and stroke.

Reality

Clinical trial results are mixed. Some trials (notably CASTA in stroke) did not meet primary endpoints; meta-analyses report modest benefits for motor recovery in stroke and cognitive outcomes in dementia. Cerebrolysin is not a cure for any neurological condition. It is one adjunctive therapy with a measurable but modest effect size in specific clinical contexts.

Myth

Because it is porcine-derived and biological, Cerebrolysin is automatically safer than synthetic peptides.

Reality

Biological origin does not equal safety. The porcine source introduces allergenicity considerations, the complex composition increases the chance of unidentified immunogenic components, and the IV route carries infusion-reaction risk that self-injected peptides do not. Approved status in many countries reflects an acceptable risk-benefit profile under clinical administration, not inherent safety.

Published Research

37 studies

Neuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions

Prospective CohortPMID: 42110924

Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies

Meta-AnalysisPMID: 41880098

[The effect of Cerebrolysin on the development of skills in patients after acute cerebrovascular accidents]

Meta-AnalysisPMID: 41782528

Cerebrolysin and Risk of Hemorrhagic Transformation: A Pooled Analysis of Recent Studies

Brief CommunicationPMID: 41775380

Cerebrolysin after Endovascular Thrombectomy in Stroke: 12-Month Functional Outcomes in a Propensity-Matched Cohort

Observational CohortPMID: 41739286

Use of nootropics in Alzheimer's disease: An analysis of regulatory positions and drug policies in the countries of the Commonwealth of Independent States

Regulatory AnalysisPMID: 41467376

Therapeutic strategies in vascular cognitive impairment: A systematic review and meta-analysis

Meta-AnalysisPMID: 41198594

C-REGS2 - A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischaemic stroke

Vosko and colleagues, International Journal of Stroke 2025 — the largest controlled Cerebrolysin dataset in existence: 1769 patients (1021 treated, 748 control) across 16 countries, enrolled 2018 to 2024, using target-trial emulation. Reported a positive primary ordinal modified Rankin Scale result at day 90 (Mann-Whitney 0.6157, P<0.0001) independent of prior thrombolysis, with no differences in safety measures. The decisive caveat is design rather than size: this was open-label and non-randomised, so it cannot answer the question the blinded trials left open, and several authors declare honoraria from the manufacturer.

Comparative Effectiveness StudyPMID: 40851188

[Cerebrolysin and the optimal timing of anticoagulation resumption in stroke: combined post hoc survival analysis of the CEREHETIS trial]

Randomized Controlled TrialPMID: 40123141

Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study

Randomized Controlled TrialPMID: 39957612

[Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study]

Randomized Controlled TrialPMID: 39435777

Add-on treatment with Cerebrolysin improves clinical symptoms in patients with ALS: results from a prospective, single-center, placebo-controlled, randomized, double-blind, phase II study

Randomized Controlled TrialPMID: 38585517

[Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation]

Meta-AnalysisPMID: 38512096

The effectiveness of cerebrolysin, a multi-modal neurotrophic factor, for treatment of post-covid-19 persistent olfactory, gustatory and trigeminal chemosensory dysfunctions: a randomized clinical trial

Randomized Controlled TrialPMID: 37950370

Cerebrolysin for acute ischaemic stroke

Ziganshina and colleagues, Cochrane Database of Systematic Reviews 2023 (CD007026.pub7) — the current version of the Cochrane review and the single most important reference on this page. Seven RCTs, 1773 participants. Conclusions verbatim: moderate-certainty evidence that Cerebrolysin probably has no beneficial effect on preventing all-cause death; moderate-certainty evidence of no beneficial effect on the total number of people with serious adverse events; and moderate-certainty evidence of a potential increase in non-fatal serious adverse events (RR 2.39, 95% CI 1.10 to 5.23), most pronounced in the 30 mL for 10 days subgroup (RR 2.87, 1.24 to 6.69). Note also what the reviewers could not assess: none of the seven trials reported poor functional outcome, defined as death or dependence at the end of follow-up — the outcome that matters most to patients. Earlier versions of this review from 2010 through 2020 are superseded by this one and are not listed separately.

Systematic ReviewPMID: 37818733

[Effects of simultaneous use of Cerebrolysin and alteplase on hemorrhagic transformation of brain infarction and functional outcome in stroke patients: CEREHETIS, a randomized, multicenter pilot trial]

Randomized Controlled TrialPMID: 37682097

Extended Poststroke Rehabilitation Combined with Cerebrolysin Promotes Upper Limb Motor Recovery in Early Subacute Phase of Rehabilitation: A Randomized Clinical Study

Randomized Controlled TrialPMID: 36837492

Prospective Randomized Control Trial to Compare the Role of Injection Cerebrolysin for 10 Days Duration Against Placebo in Operated Cases of Degenerative Cervical Myelopathy

Randomized Controlled TrialPMID: 36730671

Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials

Strilciuc and colleagues, Pharmaceuticals 2021 — 12 RCTs, 2202 participants, concluding that the analysis 'confirms the safety profile' with non-statistically significant differences between Cerebrolysin and placebo throughout. Worth reading directly against the 2023 Cochrane review, which drew on overlapping trials and found a moderate-certainty increase in non-fatal serious adverse events. Same underlying evidence, opposite conclusions — the clearest single illustration of why the provenance of a Cerebrolysin claim matters as much as its content.

Meta-AnalysisPMID: 34959697

The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review

Meta-AnalysisPMID: 34924395

Prospective Randomized Control Pilot Study to Compare the Role of Injection Cerebrolysin in Operated cases of Degenerative Cervical Myelopathy

Randomized Controlled TrialPMID: 34889883

European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke

Beghi and colleagues, European Journal of Neurology 2021 — the only Western professional-society recommendation supporting Cerebrolysin, and a necessary counterweight to the Cochrane position: it recommends Cerebrolysin 30 mL/day intravenously for at least 10 days for early neurorehabilitation after acute ischaemic stroke. Two things belong alongside it. Seven of its fifteen authors are part of the manufacturer-linked investigator network that produced CARS, CAPTAIN and C-REGS, and the Philippine Health Technology Assessment Council independently rated the underlying review 'critically low-quality' when declining to fund the drug in 2023.

GuidelinePMID: 34152062

Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series

Vester and colleagues, Neurological Sciences 2021 — the strongest evidence for the traumatic brain injury indication, pooling the two CAPTAIN phase IIIb/IV trials. 185 patients with moderate-to-severe TBI (mean Glasgow Coma Scale 10.3, mean age 45.3). Multidimensional ensemble analysis favoured Cerebrolysin at both day 30 (Mann-Whitney 0.60, p=0.0156) and day 90 (0.60, p=0.0146), effect sizes the authors characterise as small-to-medium. Two framing points: there is no Cochrane review of Cerebrolysin in TBI, so this is not counterbalanced the way the stroke and dementia literature is; and 185 patients is a small base for the conclusion that integration into guidelines should be considered.

Meta-AnalysisPMID: 33620612

Cerebrolysin for vascular dementia

Cui and colleagues, Cochrane Database of Systematic Reviews 2019 (CD008900.pub3) — the current Cochrane position on vascular dementia. Six RCTs, 597 participants, reporting improved cognition and global function but grading every outcome very low quality. The authors' own summary is unusually blunt and worth quoting in full rather than paraphrasing: the data 'are not definitive,' the included papers had high risk of bias, 'if there are benefits of Cerebrolysin, the effects may be too small to be clinically meaningful,' and 'Cerebrolysin continues to be used and promoted as a treatment for vascular dementia, but the supporting evidence base is weak.' This update added no new studies, meaning no qualifying trial in vascular dementia appeared between 2013 and 2019. Five of the six included studies were conducted in China, Russia or Romania, and where funding was disclosed, all were industry-supported.

Systematic ReviewPMID: 31710397

Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials

Meta-AnalysisPMID: 29248999

Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial

Clinical TrialPMID: 29075343

Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials

Meta-AnalysisPMID: 28707130

Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials

Meta-AnalysisPMID: 28656143

Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials

Meta-AnalysisPMID: 28458521

A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury

Meta-AnalysisPMID: 27539610

Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

Muresanu and colleagues, Stroke 2016 — the CARS primary publication, also named in this page's prose but previously uncited. 30 mL/day for 21 days starting 24 to 72 hours after stroke, paired with standardised rehabilitation. Reported a large effect on arm function at day 90 (Action Research Arm Test, Mann-Whitney 0.71, P<0.0001) and a smaller effect on global status. The authors' own framing is the important part: 'because this study was exploratory and had a relatively small sample size, the results should be confirmed in a large-scale, randomized clinical trial.'

Randomized Controlled TrialPMID: 26564102

Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials

Gauthier and colleagues, Dementia and Geriatric Cognitive Disorders 2015 — six double-blind placebo-controlled trials at 30 mL/day in mild-to-moderate Alzheimer's disease. The detail that matters is the split between endpoints and timepoints: the cognitive effect was significant at four weeks (SMD −0.40, p=0.0031) but not at six months (SMD −0.37, p=0.1710), while global clinical change remained significant at both. A treatment whose cognitive signal does not survive to six months in a progressive dementia is a weaker result than the headline conclusion of a favourable benefit-risk ratio suggests.

Meta-AnalysisPMID: 25832905

Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials

ReviewPMID: 22514795

Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA)

Heiss and colleagues, Stroke 2012 — CASTA, the largest placebo-controlled randomised trial of Cerebrolysin in acute stroke and, until this update, named twice in this page's prose without ever being cited. 1070 patients across more than 50 Asian centres, 30 mL/day for 10 days starting within 12 hours of onset. The result was plainly negative: 'the confirmatory end point showed neutral results between the treatment groups.' A favourable trend appeared in a post hoc severely-affected subgroup (NIHSS above 12), which the authors explicitly flagged as requiring confirmation in a further trial. That confirmatory trial has not been run.

Randomized Controlled TrialPMID: 22282884

Cerebrolysin: a review of its use in dementia

ReviewPMID: 19848437

Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease

Meta-AnalysisPMID: 17318304

Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons

Hartbauer, Hutter-Paier and Windisch, Journal of Neural Transmission 2001 — the primary source for what Cerebrolysin actually is: 'a mixture of 75% free amino acids and 25% low molecular weight peptides (<10 kDa)' produced by standardised enzymatic breakdown of porcine brain proteins. Note that this contradicts the 85/15 split widely quoted elsewhere. The paper also isolates the active fraction by elimination, showing that an artificial amino-acid solution did not reproduce the protection — and, strikingly, that BDNF itself failed where Cerebrolysin worked, which argues the peptide fraction does something other than simply supply BDNF-like activity.

PreclinicalPMID: 11459078

Quick Facts

Class
Neurotrophic Peptide Complex
Tier
B
Evidence
Moderate
Safety
Moderate Data
Updated
Oct 2026
Citations
37PubMed

Also known as

FPF-1070Brain-Derived Peptide Complex

Tags

NeuroprotectionCognitive EnhancementStroke RecoveryBrain Health

Related Goals

Cognitive Support

Conditions Discussed

Brain FogDepressionPost-COVID Brain FogLong COVIDNeuropathic PainMigrainesStroke Recovery

Evidence Score

Overall Confidence50%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.